(2R)-Mitiglinide-d5 calcium

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
(2R)-Mitiglinide-d5 calcium 

(2R)-Mitiglinide-d5 (calcium) 是 Mitiglinide 氘代物。Mitiglinide (KAD-1229) 属于促胰岛素化合物，是一种 ATP 敏感的 K+ 通道 (KATP channel) 拮抗剂。Mitiglinide 对 Kir6.2/SUR1 复合物 (胰腺-细胞 KATP 通道) 具有高度特异性。Mitiglinide 可用于 2 型糖尿病的研究。

(2R)-Mitiglinide-d5 calcium

(2R)-Mitiglinide-d5 calcium Chemical Structure

规格 是否有货
1 mg 询价
5 mg 询价

* Please select Quantity before adding items.

生物活性

(2R)-Mitiglinide-d5 (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

359.51

Formula

C19H19D5CaNO3+
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431(1):119-25.

    [3]. Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. May-Jun 2002;29(5-6):423-7.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务